Valneva is seeking initial approval of VLA2001 from various regulatory authorities, including the European Medicines Agency (EMA), the U.K. Medicines and Healthcare products Regulatory Agency, and the National Health Regulatory Authority in Bahrain (NHRA). The company expects potential regulatory approvals in the first quarter of 2022, with timely submission of applications.